168 related articles for article (PubMed ID: 32522077)
1. Group sequential monitoring based on the maximum of weighted log-rank statistics with the Fleming-Harrington class of weights in oncology clinical trials.
Prior TJ
Stat Methods Med Res; 2020 Dec; 29(12):3525-3532. PubMed ID: 32522077
[TBL] [Abstract][Full Text] [Related]
2. Robust group sequential designs for trials with survival endpoints and delayed response.
Ghosh P; Ristl R; König F; Posch M; Jennison C; Götte H; Schüler A; Mehta C
Biom J; 2022 Feb; 64(2):343-360. PubMed ID: 34935177
[TBL] [Abstract][Full Text] [Related]
3. A simulation-free group sequential design with max-combo tests in the presence of non-proportional hazards.
Wang L; Luo X; Zheng C
Pharm Stat; 2021 Jul; 20(4):879-897. PubMed ID: 33759337
[TBL] [Abstract][Full Text] [Related]
4. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
5. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
Mukhopadhyay P; Ye J; Anderson KM; Roychoudhury S; Rubin EH; Halabi S; Chappell RJ
JAMA Oncol; 2022 Sep; 8(9):1294-1300. PubMed ID: 35862037
[TBL] [Abstract][Full Text] [Related]
6.
Yang M; Hua Z; Xue L; Hu M
J Biopharm Stat; 2020 Mar; 30(2):244-266. PubMed ID: 31288599
[TBL] [Abstract][Full Text] [Related]
7. Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects.
Jiménez JL; Stalbovskaya V; Jones B
Pharm Stat; 2019 May; 18(3):287-303. PubMed ID: 30592138
[TBL] [Abstract][Full Text] [Related]
8. Group sequential designs for cancer immunotherapy trial with delayed treatment effect.
Wu J; Li Y; Zhu L
J Biopharm Stat; 2024 Jan; 34(1):1-15. PubMed ID: 36740768
[TBL] [Abstract][Full Text] [Related]
9. On information fraction for Fleming-Harrington type weighted log-rank tests in a group-sequential clinical trial design.
Kundu MG; Sarkar J
Stat Med; 2021 May; 40(10):2321-2338. PubMed ID: 33624861
[TBL] [Abstract][Full Text] [Related]
10. Group sequential monitoring based on the weighted log-rank test statistic with the Fleming-Harrington class of weights in cancer vaccine studies.
Hasegawa T
Pharm Stat; 2016 Sep; 15(5):412-9. PubMed ID: 27353855
[TBL] [Abstract][Full Text] [Related]
11. Design and analysis of group-sequential clinical trials based on a modestly weighted log-rank test in anticipation of a delayed separation of survival curves: A practical guidance.
Magirr D; Jiménez JL
Clin Trials; 2022 Apr; 19(2):201-210. PubMed ID: 35257619
[TBL] [Abstract][Full Text] [Related]
12. Interim monitoring using the adaptively weighted log-rank test in clinical trials for survival outcomes.
Yang S
Stat Med; 2019 Feb; 38(4):601-612. PubMed ID: 30209818
[TBL] [Abstract][Full Text] [Related]
13. A win ratio approach for comparing crossing survival curves in clinical trials.
Zheng S; Wang D; Qiu J; Chen T; Gamalo M
J Biopharm Stat; 2023 Jul; 33(4):488-501. PubMed ID: 36749067
[TBL] [Abstract][Full Text] [Related]
14. Non-proportional hazards in immuno-oncology: Is an old perspective needed?
Magirr D
Pharm Stat; 2021 May; 20(3):512-527. PubMed ID: 33350587
[TBL] [Abstract][Full Text] [Related]
15. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
Tang Y
Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
[TBL] [Abstract][Full Text] [Related]
16. Quantifying treatment differences in confirmatory trials under non-proportional hazards.
Jiménez JL
J Appl Stat; 2022; 49(2):466-484. PubMed ID: 35707213
[TBL] [Abstract][Full Text] [Related]
17. The Inverse Log-Rank Test: A Versatile Procedure for Late Separating Survival Curves.
Efird JT
Int J Environ Res Public Health; 2023 Dec; 20(24):. PubMed ID: 38131716
[TBL] [Abstract][Full Text] [Related]
18. Stratified modestly weighted log-rank tests in settings with an anticipated delayed separation of survival curves.
Magirr D; Jiménez JL
Biom J; 2023 Apr; 65(4):e2200126. PubMed ID: 36732918
[TBL] [Abstract][Full Text] [Related]
19. Statistical and practical considerations in designing of immuno-oncology trials.
Mukhopadhyay P; Huang W; Metcalfe P; Öhrn F; Jenner M; Stone A
J Biopharm Stat; 2020 Nov; 30(6):1130-1146. PubMed ID: 33706684
[TBL] [Abstract][Full Text] [Related]
20. Sequential tests for non-proportional hazards data.
Brückner M; Brannath W
Lifetime Data Anal; 2017 Jul; 23(3):339-352. PubMed ID: 26969674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
